首页 > 文章详情

【2023 SICS】Rina Yoo教授专访：19届上海国际大肠癌高峰论坛促进中韩医生学习、交流及友好合作

2023年07月14日

来源：肿瘤资讯

^{_{Rina Yoo教授专访}}

19届上海国际大肠癌高峰论坛促进中韩医生学习、交流及友好合作

第19届上海国际大肠癌高峰论坛于2023年6月17日在上海顺利召开。本次会议汇集了多位院士及海内外结直肠癌学术领军专家，围绕结直肠癌诊疗最新研究进展和方向展开学术汇报，可谓是精彩纷呈。【肿瘤资讯】小编亲临现场，特邀韩国天主教大学首尔圣玛丽医院的Dr. Rina Yoo分享对于侧方淋巴结清扫术以及此次论坛意义的见解。

侧方淋巴结清扫仍具争议

Rina Yoo：西方与东方之间关于侧方淋巴结清扫（LLND）的争辩已有很长的历史。在我的演讲中，我曾提到韩国的指南内容：若局部进展期直肠癌患者具有侧方淋巴结转移高危风险，我们建议首先行术前放化疗，随后评估治疗反应。若患者的反应良好，则患者可接受全直肠系膜切除术（TME），无需LLND；若患者的反应较差或中等，我们则需要考虑侧方淋巴结清扫对于患者的利弊。原因是，有时即使避免了侧方淋巴结清扫，肿瘤细胞可能残留而无法被根除，从而存在复发的可能。在此背景下，如果肿瘤具有侵袭性且对除LLND之外的其他治疗方法反应较好，那么，我们需要根据风险进行分层，再判断是否要行LLND。

分子靶向领域进展至关重要

Rina Yoo：的确，今年的日程令人印象深刻。我最关注的是分子靶向治疗。当演讲者们在讲台上胸有成竹地介绍这一领域的最新进展以及他们的研究成果，这给我留下了很深的印象。我认为，分子靶向治疗是一个非常重要的领域，基于最新研究结果，我们可以应对那些当前治疗效果不佳的肿瘤细胞。

大肠癌高峰论坛促进中韩医生学习、交流、合作

Rina Yoo：我认为这是一个难得的机会，作为韩国的嘉宾受邀来到中国进行演讲。中国医生和韩国医生互动交流，或许在将来我们会有更多合作的机会，这对于提升医学知识水平、改善患者管理来说至关重要。

The 19th Shanghai International Colorectal Cancer Summit provides important learning and interactive opportunities for Chinese and Korean doctors

The 19th Shanghai International Colorectal Cancer Forum was successfully held in Shanghai on June 17, 2023. The Forum brought together many academicians and leading experts in colorectal cancer at home and abroad to present the latest research progress and direction of colorectal cancer diagnosis and treatment, which can be described as wonderful. Dr. Rina Yoo from Korea from St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea was invited to be interviewed by Oncology News to share her insights on lateral lymph node dissection and the significance of this forum.

Lateral lymph node dissection remains controversial

Rina Yoo：There is a very long history of this debate between western versus eastern. In my speech, I actually mentioned what the Korean guideline was.We think, if a locally advanced rectal cancer patient with a lateral pelvic lymph node metastasis, then firstly we recommend the patient to get a neoadjuvant chemoradiotherapy. After that, we assess the response. If the patient has a good response, we definitely recommend TME without lateral lymph node dissection（LLND）.If the patient shows little or moderate response, we are going to think whether LLND is beneficial or harmful to the patient. Because, even if we try to get rid of the LLND sometimes, tumor cells may remain and not be eradicated, thus the possibility of recurrence exists.If the tumor is aggressive and responds well to treatments other than LLND, then we have to think based on the risk stratification before judging whether to perform LLND or not.

Progress in molecular targeting is critical

Rina Yoo：Definitely, the programme this year was impressive. My main focus was on molecular targeted therapies. I was very impressed when the speakers were proud and presented with confidence the latest advances in this field and their research results. I think that molecular targeted therapy is a very important area where, based on the latest researches, we can tackle those tumor cells that is not responsive to the currently available treatment.

The Colorectal Cancer Forum promotes learning, exchange and cooperation between Chinese and Korean doctors

Rina Yoo：I think this is a huge opportunity to be invited to China as a speaker from Korea. The interaction between Chinese doctors and Korean doctors, and perhaps in the future we will have more opportunities for cooperation, is really important to improve medical knowledge and improve patient management.

责任编辑：肿瘤资讯-Bree
排版编辑：肿瘤资讯-Lynn

点击链接查看论坛回放：https://mm.sciconf.cn/cn/minisite/content/18418?m=778603

参考文献

1.安柯, 顾晋. 直肠癌侧方淋巴结的概念与侧方淋巴结清扫的争议[J]. 中华胃肠外科杂志, 2022, 25(8): 694-698. DOI: 10.3760/cma.j.cn441530-20220725-00326.